Evidence map›Paper›PMID 33069251›Full record

ArticleAlzheimer's research & therapy2020

Aß40 displays amyloidogenic properties in the non-transgenic mouse brain but does not exacerbate Aß42 toxicity in Drosophila.

Lorena De Mena, Michael A Smith, Jason Martin, Katie L Dunton, Carolina Ceballos-Diaz, Karen R Jansen-West, Pedro E Cruz, Kristy D Dillon, Diego E Rincon-Limas, Todd E Golde and 2 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. TargetingInternational journal of molecular sciences · 2022
    Article
  2. Fecal Implants FromFrontiers in behavioral neuroscience · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Lorena De MenaDepartment of Neurology, McKnight Brain Institute, University of Florida and Norman Fixel Institute for Neurological Diseases, Gainesville, FL, USA.
Michael A SmithCenter for Translational Research in Neurodegenerative Disease and Department of Neuroscience, Gainesville, FL, USA.
Jason MartinCenter for Translational Research in Neurodegenerative Disease and Department of Neuroscience, Gainesville, FL, USA.
Katie L DuntonCenter for Translational Research in Neurodegenerative Disease and Department of Neuroscience, Gainesville, FL, USA.
Carolina Ceballos-DiazCenter for Translational Research in Neurodegenerative Disease and Department of Neuroscience, Gainesville, FL, USA.
Karen R Jansen-WestDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Pedro E CruzCenter for Translational Research in Neurodegenerative Disease and Department of Neuroscience, Gainesville, FL, USA.
Kristy D DillonCenter for Translational Research in Neurodegenerative Disease and Department of Neuroscience, Gainesville, FL, USA.
Diego E Rincon-LimasDepartment of Neurology, McKnight Brain Institute, University of Florida and Norman Fixel Institute for Neurological Diseases, Gainesville, FL, USA.
Todd E GoldeCenter for Translational Research in Neurodegenerative Disease and Department of Neuroscience, Gainesville, FL, USA.
Brenda D MooreCenter for Translational Research in Neurodegenerative Disease and Department of Neuroscience, Gainesville, FL, USA. brendar@ufl.edu.
Yona LevitesCenter for Translational Research in Neurodegenerative Disease and Department of Neuroscience, Gainesville, FL, USA. levites.yona@ufl.edu.ORCID 0000-0001-6925-4525
University of Florida · USMayo Clinic in Florida · US

Funding

Elucidating factors that modulate tauopathy and cellular degeneration to guide therapeutic developmentRF1AG064914 · NIA · UNIVERSITY OF FLORIDA · PI GOLDE, TODD E, LEWIS, JADA M · 2019 to 2019
$2.5M
NIA NIH HHS RF1 AG064914NIH HHS AG046139NIH HHS AG047266NIH HHS AG064914
6 · The paper itself

Abstract

backgroundSelf-assembly of the amyloid-β (Aβ) peptide into aggregates, from small oligomers to amyloid fibrils, is fundamentally linked with Alzheimer's disease (AD). However, it is clear that not all forms of Aβ are equally harmful and that linking a specific aggregate to toxicity also depends on the assays and model systems used (Haass et al., J Biol. Chem 269:17741-17748, 1994; Borchelt et al., Neuron 17:1005-1013, 1996). Though a central postulate of the amyloid cascade hypothesis, there remain many gaps in our understanding regarding the links between Aβ deposition and neurodegeneration.

methodsIn this study, we examined familial mutations of Aβ that increase aggregation and oligomerization, E22G and ΔE22, and induce cerebral amyloid angiopathy, E22Q and D23N. We also investigated synthetic mutations that stabilize dimerization, S26C, and a phospho-mimetic, S8E, and non-phospho-mimetic, S8A. To that end, we utilized BRI2-Aβ fusion technology and rAAV2/1-based somatic brain transgenesis in mice to selectively express individual mutant Aβ species in vivo. In parallel, we generated PhiC31-based transgenic Drosophila melanogaster expressing wild-type (WT) and Aβ40 and Aβ42 mutants, fused to the Argos signal peptide to assess the extent of Aβ42-induced toxicity as well as to interrogate the combined effect of different Aβ40 and Aβ42 species.

resultsWhen expressed in the mouse brain for 6 months, Aβ42 E22G, Aβ42 E22Q/D23N, and Aβ42WT formed amyloid aggregates consisting of some diffuse material as well as cored plaques, whereas other mutants formed predominantly diffuse amyloid deposits. Moreover, while Aβ40WT showed no distinctive phenotype, Aβ40 E22G and E22Q/D23N formed unique aggregates that accumulated in mouse brains. This is the first evidence that mutant Aβ40 overexpression leads to deposition under certain conditions. Interestingly, we found that mutant Aβ42 E22G, E22Q, and S26C, but not Aβ40, were toxic to the eye of Drosophila. In contrast, flies expressing a copy of Aβ40 (WT or mutants), in addition to Aβ42WT, showed improved phenotypes, suggesting possible protective qualities for Aβ40.

conclusionsThese studies suggest that while some Aβ40 mutants form unique amyloid aggregates in mouse brains, they do not exacerbate Aβ42 toxicity in Drosophila, which highlights the significance of using different systems for a better understanding of AD pathogenicity and more accurate screening for new potential therapies.

Indexed as

Alzheimer DiseaseDrosophilaAmyloid beta-PeptidesAnimalsBrainDrosophila melanogasterMicePeptide FragmentsAmyloid beta-PeptidesPeptide FragmentsAlzheimer’s diseaseAmyloid plaquesCognitive impairmentDrosophilaFruit fly

Identifiers

PMID33069251
PMCPMC7568834
OpenAlexW3092916995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.